Showing results (151-160 of 169) with videos related to
Sort By:
Pageof 17
Nature Medicine|August 10, 2023
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trialMarion Thibaudin, Jean-David Fumet, Benoist Chibaudel, et al.European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)Guillem Argilés, Nuria Mulet, Manuel Valladares-Ayerbes, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.Nature Medicine|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trialTina Cascone, Laura Bonanno, Florian Guisier, et al.European Journal of Cancer (Oxford, England : 1990)|May 27, 2019
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trialDavid Malka, Eric François, Frédérique Penault-Llorca, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 TrialDaniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2018
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028Patrick A Ott, Yung-Jue Bang, Sarina A Piha-Paul, et al.The Lancet. Oncology|January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trialLuis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.The Oncologist|March 13, 2020
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)Johanna C Bendell, Tamara Sauri, Antonio Cubillo Gracián, et al.Pageof 17